Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance.
Triple negative breast cancer (TNBC) is a heterogeneous form of malignant disease. Due to lack of proper therapeutic target treatment options are restricted and relies primarily on chemotherapeutic modality for treatment of patients. Despite significant early regression of the disease in response to chemotherapy, complete cure is not assured with development of resistant tumors which is difficult to manage clinically. In the last decades, the regulation and contribution of microRNAs in tumorigenesis including breast cancers have been well-documented. Thus, here it is hypothesized that by identifying the microRNAs responsible for chemoresistance in TNBC and targeting the microRNAs along with chemotherapeutic approaches might exert an improved response. To accomplish this, an in vivo screening has to be performed by transfecting tumor cell line with lentiviral pool of library expressing microRNAs. Following treatment of primary tumors in mice and growth of relapsed tumors, microRNA profile has to be analyzed by qRT-PCR and sequencing to detect the microRNAs contributing to the chemoresistance which can be targeted by anti-microRNA strategies.